AstraZeneca (LON:AZN) Share Price Crosses Above 200-Day Moving Average – Here’s What Happened

AstraZeneca PLC (LON:AZN) shares passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of £114.96 ($142.61) and traded as high as £119.78 ($148.59). AstraZeneca shares last traded at £117.86 ($146.21), with a volume of 2,997,711 shares trading hands.

Analysts Set New Price Targets

Several research firms have commented on AZN. JPMorgan Chase & Co. reissued an “overweight” rating and set a £140 ($173.68) price target on shares of AstraZeneca in a research report on Friday, November 22nd. Berenberg Bank restated a “buy” rating and issued a GBX 140 ($1.74) target price on shares of AstraZeneca in a research note on Monday, January 27th. Finally, Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Thursday, November 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of GBX 7,935.67 ($98.45).

AstraZeneca Stock Down 1.6 %

The business’s 50-day simple moving average is £107.76 and its 200-day simple moving average is £114.98. The company has a market capitalization of £179.80 billion, a PE ratio of 3,682.54, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97.

Insider Buying and Selling at AstraZeneca

In related news, insider Tony Mok purchased 1,500 shares of AstraZeneca stock in a transaction that occurred on Tuesday, November 19th. The stock was bought at an average cost of £126.80 ($157.30) per share, for a total transaction of £190,200 ($235,950.87). Also, insider Pascal Soriot acquired 20,000 shares of the stock in a transaction on Thursday, November 14th. The stock was bought at an average price of £102.03 ($126.57) per share, for a total transaction of £2,040,600 ($2,531,447.71). 0.04% of the stock is owned by corporate insiders.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.